A plasma-based assay for assessment of tumour mutational burden in patients with metastatic non-small cell lung cancer in the first-line treatment setting: Results from the MYSTIC study. (March 2019) - Si, H.; Kuziora, M.; Helman, E.; Quinn, K.; Brohawn, P.Z.; Raja, R.; Ranade, K.; Higgs, B.W.